Jiangsu Bioperfectus Technologies Co Ltd
SSE:688399
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/E
Price to Earnings (P/E) ratio shows how much investors pay for each dollar of a company`s earnings. It`s calculated by dividing the company`s market value by its total earnings.
Price to Earnings (P/E) ratio shows how much investors pay for each dollar of a company`s earnings. It`s calculated by dividing the company`s market value by its total earnings.
Valuation Scenarios
If P/E returns to its 5-Year Average (4.8), the stock would be worth ¥-1.49 (102% downside from current price).
| Scenario | P/E Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | -199.5 | ¥61.75 |
0%
|
| 5-Year Average | 4.8 | ¥-1.49 |
-102%
|
| Industry Average | 33.5 | ¥-10.38 |
-117%
|
| Country Average | 29.6 | ¥-9.17 |
-115%
|
Forward P/E
Today’s price vs future net income
Peer Comparison
| Market Cap | P/E | ||||
|---|---|---|---|---|---|
| CN |
|
Jiangsu Bioperfectus Technologies Co Ltd
SSE:688399
|
5.2B CNY | -199.5 | |
| JP |
|
Hoya Corp
TSE:7741
|
9.8T JPY | 39.3 | |
| US |
M
|
Medline Inc
NASDAQ:MDLN
|
58.4B USD | 0 | |
| CH |
|
Alcon AG
SIX:ALC
|
28.4B CHF | 36.3 | |
| DK |
|
Coloplast A/S
CSE:COLO B
|
88.8B DKK | 22.4 | |
| US |
|
Align Technology Inc
NASDAQ:ALGN
|
12.6B USD | 30.6 | |
| KR |
H
|
HLB Inc
KOSDAQ:028300
|
8.1T KRW | -36.5 | |
| UK |
|
ConvaTec Group PLC
LSE:CTEC
|
4.1B GBP | 31.2 | |
| CN |
|
Shenzhen New Industries Biomedical Engineering Co Ltd
SZSE:300832
|
37.9B CNY | 23 | |
| CN |
|
Intco Medical Technology Co Ltd
SZSE:300677
|
37.3B CNY | 21.9 | |
| JP |
A
|
Asahi Intecc Co Ltd
TSE:7747
|
875B JPY | 49.5 |
Market Distribution
| Min | 0 |
| 30th Percentile | 17.1 |
| Median | 29.6 |
| 70th Percentile | 57.7 |
| Max | 43 569.3 |
Other Multiples
Jiangsu Bioperfectus Technologies Co Ltd
Glance View
Jiangsu Bioperfectus Technologies Co., Ltd. engages in the research, development, production, and sale of in vitro diagnostic reagents and supporting testing instruments. The company is headquartered in Taizhou, Jiangsu and currently employs 765 full-time employees. The company went IPO on 2019-12-05. The firm's products mainly include in vitro diagnostic reagents, supporting testing instruments and in vitro testing services. Its products are mainly used in the fields of infectious disease prevention and control, clinical testing, large-scale population screening, as well as prenatal and postnatal care management. The firm mainly conducts its businesses in domestic and overseas markets.
